Invention Grant
- Patent Title: Sulphamoylaryl derivatives and use thereof as medicaments for the treatment of liver fibrosis
-
Application No.: US16484435Application Date: 2018-02-06
-
Publication No.: US10654837B2Publication Date: 2020-05-19
- Inventor: Zhao-Kui Wan , Haibing Guo , Koen Vandyck , Pierre Jean-Marie Bernard Raboisson , Abdellah Tahri
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5481a166 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@46b50b57
- International Application: PCT/CN2018/075362 WO 20180206
- International Announcement: WO2018/145620 WO 20180816
- Main IPC: C07D405/12
- IPC: C07D405/12 ; C07D401/12 ; C07D211/58 ; C07D307/22 ; C07D305/04 ; C07D417/12 ; C07D213/75 ; C07D309/14 ; C07C311/16 ; C07C311/29 ; A61P1/16 ; A61K45/06
Abstract:
Potent 5-HT2B antagonist of Formula (A), including stereochemically isomeric forms, and salts, hydrates, solvates thereof and their use wherein R1 to R4 and Ar have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them, alone or in combination with other drugs, in fibrosis and/or cirrhosis prevention or therapy.
Information query
